1. Home
  2. ATEN vs KALV Comparison

ATEN vs KALV Comparison

Compare ATEN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$26.74

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.67

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
KALV
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
ATEN
KALV
Price
$26.74
$26.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$26.33
$32.60
AVG Volume (30 Days)
990.7K
2.7M
Earning Date
04-28-2026
07-09-2026
Dividend Yield
0.90%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$235,429,000.00
$50,000,000.00
Revenue This Year
$13.02
$185.42
Revenue Next Year
$10.82
$59.23
P/E Ratio
$46.53
N/A
Revenue Growth
2.36
495.66
52 Week Low
$15.92
$9.83
52 Week High
$28.59
$26.76

Technical Indicators

Market Signals
Indicator
ATEN
KALV
Relative Strength Index (RSI) 59.43 75.23
Support Level $17.08 $14.43
Resistance Level $28.59 N/A
Average True Range (ATR) 1.05 0.97
MACD -0.11 0.53
Stochastic Oscillator 59.18 98.83

Price Performance

Historical Comparison
ATEN
KALV

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: